These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8405139)

  • 1. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes.
    Riedel M; Wiese A; Schürmeyer TH; Brabant G
    Exp Clin Endocrinol; 1993; 101(2):106-11. PubMed ID: 8405139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.
    Gagliardi L; Nenke MA; Thynne TR; von der Borch J; Rankin WA; Henley DE; Sorbello J; Inder WJ; Torpy DJ
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4149-57. PubMed ID: 25127090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency.
    Bleicken B; Hahner S; Loeffler M; Ventz M; Decker O; Allolio B; Quinkler M
    Clin Endocrinol (Oxf); 2010 Mar; 72(3):297-304. PubMed ID: 19508599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency.
    Ekman B; Bachrach-Lindström M; Lindström T; Wahlberg J; Blomgren J; Arnqvist HJ
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):18-25. PubMed ID: 22288685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement.
    Ross IL; Levitt NS; Van der Walt JS; Schatz DA; Johannsson G; Haarburger DH; Pillay TS
    Horm Metab Res; 2013 Jan; 45(1):62-8. PubMed ID: 22893258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study.
    Harbeck B; Kropp P; Mönig H
    Appl Psychophysiol Biofeedback; 2009 Jun; 34(2):113-9. PubMed ID: 19387826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metabolic assessment of hydrocortisone replacement therapy in patients with primary adrenocortical insufficiency].
    Fichna M; Gryczyńska M; Sowińska A; Sowiński J
    Przegl Lek; 2011; 68(2):96-102. PubMed ID: 21751518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.
    Oksnes M; Björnsdottir S; Isaksson M; Methlie P; Carlsen S; Nilsen RM; Broman JE; Triebner K; Kämpe O; Hulting AL; Bensing S; Husebye ES; Løvås K
    J Clin Endocrinol Metab; 2014 May; 99(5):1665-74. PubMed ID: 24517155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary cortisol day curves in assessing glucocorticoid replacement therapy in Addison's disease.
    Smans L; Lentjes E; Hermus A; Zelissen P
    Hormones (Athens); 2013; 12(1):93-100. PubMed ID: 23624135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional glucocorticoid replacement overtreats adult hypopituitary patients with partial ACTH deficiency.
    Agha A; Liew A; Finucane F; Baker L; O'Kelly P; Tormey W; Thompson CJ
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):688-93. PubMed ID: 15163331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism.
    Wichers M; Springer W; Bidlingmaier F; Klingmüller D
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):759-65. PubMed ID: 10468948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroids and the cardiovascular response to stress: a pilot study of the 35% CO2 challenge in Addison's disease.
    Kaye JM; Lightman SL
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):282-6. PubMed ID: 16918945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density is reduced in female but not male subjects with Addison's disease.
    Florkowski CM; Holmes SJ; Elliot JR; Donald RA; Espiner EA
    N Z Med J; 1994 Feb; 107(972):52-3. PubMed ID: 8115069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease.
    Ross IL; Lacerda M; Pillay TS; Blom DJ; Johannsson G; Dave JA; Levitt NS; Haarburger D; van der Walt JS
    Horm Metab Res; 2016 Dec; 48(12):814-821. PubMed ID: 27813051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.
    Giordano R; Guaraldi F; Marinazzo E; Fumarola F; Rampino A; Berardelli R; Karamouzis I; Lucchiari M; Manetta T; Mengozzi G; Arvat E; Ghigo E
    Endocrine; 2016 Feb; 51(2):360-8. PubMed ID: 26184416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
    Björnsdottir S; Øksnes M; Isaksson M; Methlie P; Nilsen RM; Hustad S; Kämpe O; Hulting AL; Husebye ES; Løvås K; Nyström T; Bensing S
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):28-35. PubMed ID: 25400085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oedema in patients with Addison's disease on replacement therapy: glucocorticoid excess and mineralocorticoid deficiency?
    Flynn MD; Shore AC; Sandeman DE; Mawson D; Donohoe M; Tooke JE
    QJM; 1994 Jul; 87(7):437-41. PubMed ID: 7922296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired health-related quality of life in Addison's disease--impact of replacement therapy, comorbidities and socio-economic factors.
    Kluger N; Matikainen N; Sintonen H; Ranki A; Roine RP; Schalin-Jäntti C
    Clin Endocrinol (Oxf); 2014 Oct; 81(4):511-8. PubMed ID: 24801591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to low-dose pulsatile cortisol in Addison's disease with suspected corticotropinoma.
    Carr DB; Fisher JE; Rosenblatt M
    Horm Metab Res; 1986 Aug; 18(8):569-73. PubMed ID: 3019857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.